{"commentary":{"count":50,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":27,"youtube":14,"x_thread":9},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02952534\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"TRITON2","nct_id":"NCT02952534","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=triton2-nct02952534. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"TRITON2","arms":[{"description":"Oral rucaparib (monotherapy)","label":"Rucaparib","type":"EXPERIMENTAL"}],"collaborators":["Foundation Medicine"],"completion_date":{"date":"2021-07-27","type":"ACTUAL"},"conditions":["Metastatic Castration Resistant Prostate Cancer"],"enrollment":{"count":277,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Rucaparib","type":"DRUG"}],"last_update":"2023-06-09","lead_sponsor":"pharmaand GmbH","official_title":"TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-07-18","type":"ACTUAL"},"primary_outcomes":[{"measure":"Confirmed Objective Response Rate (ORR) by Gene in Patients With Measurable Disease at Baseline Per Central Independent Radiology Review (IRR)","timeFrame":"Assessments every 8 weeks from study day 1 for the first 24 weeks, and then every 12 weeks until disease progression, death, or initiation of subsequent treatment. Total follow-up was up to approximately 3 years."}],"references":[{"citation":"Abida W, Campbell D, Patnaik A, Bryce AH, Shapiro J, Bambury RM, Zhang J, Burke JM, Castellano D, Font A, Ganju V, Hardy-Bessard AC, McDermott R, Sautois B, Spaeth D, Voog E, Piulats JM, Pintus E, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Loehr A, Despain D, Simmons AD, Dowson M, Go J, Watkins SP, Chowdhury S. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. Eur Urol. 2023 Sep;84(3):321-330. doi: 10.1016/j.eururo.2023.05.021. Epub 2023 Jun 3.","pmid":"37277275","type":"DERIVED"},{"citation":"Collins K, Cheng L. Reprint of: morphologic spectrum of treatment-related changes in prostate tissue and prostate cancer: an updated review. Hum Pathol. 2023 Mar;133:92-101. doi: 10.1016/j.humpath.2023.02.007. Epub 2023 Mar 8.","pmid":"36898948","type":"DERIVED"},{"citation":"Green ML, Ma SC, Goble S, Giordano H, Maloney L, Simmons AD, Beltman J, Harding TC, Xiao JJ. Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors. Cancer Chemother Pharmacol. 2022 May;89(5):671-682. doi: 10.1007/s00280-022-04413-7. Epub 2022 Apr 10.","pmid":"35397664","type":"DERIVED"},{"citation":"Maia MC, Salgia M, Pal SK. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nat Rev Urol. 2020 May;17(5):271-291. doi: 10.1038/s41585-020-0297-9. Epub 2020 Mar 17.","pmid":"32203306","type":"DERIVED"}],"start_date":{"date":"2017-02-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","url":"https://clinicaltrials.gov/study/NCT02952534"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/triton2-nct02952534"}